liesje schreef op 12 november 2013 10:03:
We believe the Viropharma acquisition is supportive for Pharming's business
case. Even if Pharming’s Ruconest could gain only a single digit share of the
US HAE market, its current trading levels, representing a € 53m market cap,
indicate a strong undervaluation. With a likely approval of Ruconest in April
2014, we reiterate our Buy rating and target price.